Casdin Capital raised its stake in GeneDx Holdings (WGS) by 23.28% during the second quarter of 2026, according to a recent SEC filing. The investment firm, which specializes in life sciences and healthcare, increased its holding to 3.71 million shares, valued at approximately $254.50 million as of June 30, 2026. This move comes as GeneDx reported record test volumes and an earlier-than-expected return to adjusted profitability in the same quarter.
It is important to note that 13F filings are submitted to the SEC quarterly and reflect a snapshot of an investment manager's portfolio on a specific date in the past. Therefore, this filing from August 14, 2026, details Casdin Capital's position at the end of June 2026 and may not represent their current holdings. Eli Casdin, the founder of Casdin Capital, also serves as a director on the board of GeneDx.